Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study

Yoshitaka Nishikawa; Takahiro Horimatsu; Shiro Oka; Takeshi Yamada; Keigo Mitsui; Hironori Yamamoto; Keiichi Takahashi; Akio Shiomi; Kinichi Hotta; Yoji Takeuchi; Toshio Kuwai; Fumio Ishida; Shin Ei Kudo; Shoichi Saito; Masashi Ueno; Eiji Sunami; Tomoki Yamano; Michio Itabashi; Kazuo Ohtsuka; Yusuke Kinugasa; Takayuki Matsumoto; Tamotsu Sugai; Toshio Uraoka; Koichi Kurahara; Shigeki Yamaguchi; Tomohiro Kato; Masazumi Okajima; Hiroshi Kashida; Fumihiko Fujita; Hiroaki Ikematsu; Masaaki Ito; Motohiro Esaki; Masaya Kawai; Takashi Yao; Madoka Hamada; Keiji Koda; Yasumori Fukai; Koji Komori; Yusuke Saitoh; Yukihide Kanemitsu; Hiroyuki Takamaru; Kazutaka Yamada; Hiroaki Nozawa; Tetsuji Takayama; Kazutomo Togashi; Eiji Shinto; Takehiro Torisu; Akira Toyoshima; Naoki Ohmiya; Takeshi Kato; Eigo Otsuji; Shinji Nagata; Yojiro Hashiguchi; Kenichi Sugihara; Yoichi Ajioka; Shinji Tanaka

doi:10.1200/GO.23.00392

Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study

Yoshitaka Nishikawa, Takahiro Horimatsu, Shiro Oka, Takeshi Yamada, Keigo Mitsui, Hironori Yamamoto, Keiichi Takahashi, Akio Shiomi, Kinichi Hotta, Yoji Takeuchi, Toshio Kuwai, Fumio Ishida, Shin Ei Kudo, Shoichi Saito, Masashi Ueno, Eiji Sunami, Tomoki Yamano, Michio Itabashi, Kazuo Ohtsuka, Yusuke KinugasaTakayuki Matsumoto, Tamotsu Sugai, Toshio Uraoka, Koichi Kurahara, Shigeki Yamaguchi, Tomohiro Kato, Masazumi Okajima, Hiroshi Kashida, Fumihiko Fujita, Hiroaki Ikematsu, Masaaki Ito, Motohiro Esaki, Masaya Kawai, Takashi Yao, Madoka Hamada, Keiji Koda, Yasumori Fukai, Koji Komori, Yusuke Saitoh, Yukihide Kanemitsu, Hiroyuki Takamaru, Kazutaka Yamada, Hiroaki Nozawa, Tetsuji Takayama, Kazutomo Togashi, Eiji Shinto, Takehiro Torisu, Akira Toyoshima, Naoki Ohmiya, Takeshi Kato, Eigo Otsuji, Shinji Nagata, Yojiro Hashiguchi, Kenichi Sugihara, Yoichi Ajioka, Shinji Tanaka

Department of Advanced Endoscopy

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

PURPOSELimited information is available regarding the characteristics and outcomes of stage IV small bowel adenocarcinoma (SBA) in Japan. This study examined the clinical and pathological characteristics and outcomes according to the treatment strategies in patients with stage IV SBA.METHODSThis retrospective observational study used the data of patients with jejunal or ileal adenocarcinoma collected by the Small Bowel Malignant Tumor Project of the Japanese Society for Cancer of the Colon and Rectum. Descriptive statistics were expressed as the mean (standard deviation) or median (range). Survival analysis was performed using Kaplan-Meier curves and pairwise log-rank tests.RESULTSData from 128 patients were analyzed. The treatment strategies were chemotherapy alone (26 of 128, 20.3%), surgery alone (including palliative surgery; 21 of 128, 16.4%), surgery + chemotherapy (74 of 128, 57.8%), and best supportive care (7 of 128, 5.5%). The median (range) overall survival was 16 (0-125) months overall, and 11 (1-38) months, 8 (0-80) months, 18 (0-125) months, and 0 (0-1) months for the chemotherapy, surgery, surgery + chemotherapy, and best supportive care groups, respectively. Three main categories of chemotherapeutic regimen were used: a combination of fluoropyrimidine and oxaliplatin (F + Ox), fluoropyrimidine and irinotecan (F + Iri), and single-agent fluoropyrimidine. Among patients treated with chemotherapy, the median (range) OS was 16 (1-106) months overall, and 17 (1-87) months, 29 (7-39) months, and 16 (1-106) months in patients treated with fluoropyrimidine, F + Iri, and F + Ox, respectively.CONCLUSIONPatients treated with surgery, chemotherapy, or both had a better prognosis than those who received best supportive care. Among patients who received chemotherapy, survival did not differ according to the chemotherapeutic regimen.

Original language	English
Article number	e2300392
Journal	JCO Global Oncology
Volume	10
DOIs	https://doi.org/10.1200/GO.23.00392
Publication status	Published - 2024

All Science Journal Classification (ASJC) codes

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/GO.23.00392

Cite this

Nishikawa, Y., Horimatsu, T., Oka, S., Yamada, T., Mitsui, K., Yamamoto, H., Takahashi, K., Shiomi, A., Hotta, K., Takeuchi, Y., Kuwai, T., Ishida, F., Kudo, S. E., Saito, S., Ueno, M., Sunami, E., Yamano, T., Itabashi, M., Ohtsuka, K., ... Tanaka, S. (2024). Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study. JCO Global Oncology, 10, Article e2300392. https://doi.org/10.1200/GO.23.00392

@article{da7430a3b0134dd68c89be468ba6fb22,

title = "Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study",

abstract = "PURPOSELimited information is available regarding the characteristics and outcomes of stage IV small bowel adenocarcinoma (SBA) in Japan. This study examined the clinical and pathological characteristics and outcomes according to the treatment strategies in patients with stage IV SBA.METHODSThis retrospective observational study used the data of patients with jejunal or ileal adenocarcinoma collected by the Small Bowel Malignant Tumor Project of the Japanese Society for Cancer of the Colon and Rectum. Descriptive statistics were expressed as the mean (standard deviation) or median (range). Survival analysis was performed using Kaplan-Meier curves and pairwise log-rank tests.RESULTSData from 128 patients were analyzed. The treatment strategies were chemotherapy alone (26 of 128, 20.3%), surgery alone (including palliative surgery; 21 of 128, 16.4%), surgery + chemotherapy (74 of 128, 57.8%), and best supportive care (7 of 128, 5.5%). The median (range) overall survival was 16 (0-125) months overall, and 11 (1-38) months, 8 (0-80) months, 18 (0-125) months, and 0 (0-1) months for the chemotherapy, surgery, surgery + chemotherapy, and best supportive care groups, respectively. Three main categories of chemotherapeutic regimen were used: a combination of fluoropyrimidine and oxaliplatin (F + Ox), fluoropyrimidine and irinotecan (F + Iri), and single-agent fluoropyrimidine. Among patients treated with chemotherapy, the median (range) OS was 16 (1-106) months overall, and 17 (1-87) months, 29 (7-39) months, and 16 (1-106) months in patients treated with fluoropyrimidine, F + Iri, and F + Ox, respectively.CONCLUSIONPatients treated with surgery, chemotherapy, or both had a better prognosis than those who received best supportive care. Among patients who received chemotherapy, survival did not differ according to the chemotherapeutic regimen.",

author = "Yoshitaka Nishikawa and Takahiro Horimatsu and Shiro Oka and Takeshi Yamada and Keigo Mitsui and Hironori Yamamoto and Keiichi Takahashi and Akio Shiomi and Kinichi Hotta and Yoji Takeuchi and Toshio Kuwai and Fumio Ishida and Kudo, {Shin Ei} and Shoichi Saito and Masashi Ueno and Eiji Sunami and Tomoki Yamano and Michio Itabashi and Kazuo Ohtsuka and Yusuke Kinugasa and Takayuki Matsumoto and Tamotsu Sugai and Toshio Uraoka and Koichi Kurahara and Shigeki Yamaguchi and Tomohiro Kato and Masazumi Okajima and Hiroshi Kashida and Fumihiko Fujita and Hiroaki Ikematsu and Masaaki Ito and Motohiro Esaki and Masaya Kawai and Takashi Yao and Madoka Hamada and Keiji Koda and Yasumori Fukai and Koji Komori and Yusuke Saitoh and Yukihide Kanemitsu and Hiroyuki Takamaru and Kazutaka Yamada and Hiroaki Nozawa and Tetsuji Takayama and Kazutomo Togashi and Eiji Shinto and Takehiro Torisu and Akira Toyoshima and Naoki Ohmiya and Takeshi Kato and Eigo Otsuji and Shinji Nagata and Yojiro Hashiguchi and Kenichi Sugihara and Yoichi Ajioka and Shinji Tanaka",

note = "Publisher Copyright: {\textcopyright} 2024 American Society of Clinical Oncology.",

year = "2024",

doi = "10.1200/GO.23.00392",

language = "English",

volume = "10",

journal = "JCO Global Oncology",

issn = "2378-9506",

publisher = "American Society of Clinical Oncology",

}

Nishikawa, Y, Horimatsu, T, Oka, S, Yamada, T, Mitsui, K, Yamamoto, H, Takahashi, K, Shiomi, A, Hotta, K, Takeuchi, Y, Kuwai, T, Ishida, F, Kudo, SE, Saito, S, Ueno, M, Sunami, E, Yamano, T, Itabashi, M, Ohtsuka, K, Kinugasa, Y, Matsumoto, T, Sugai, T, Uraoka, T, Kurahara, K, Yamaguchi, S, Kato, T, Okajima, M, Kashida, H, Fujita, F, Ikematsu, H, Ito, M, Esaki, M, Kawai, M, Yao, T, Hamada, M, Koda, K, Fukai, Y, Komori, K, Saitoh, Y, Kanemitsu, Y, Takamaru, H, Yamada, K, Nozawa, H, Takayama, T, Togashi, K, Shinto, E, Torisu, T, Toyoshima, A, Ohmiya, N, Kato, T, Otsuji, E, Nagata, S, Hashiguchi, Y, Sugihara, K, Ajioka, Y & Tanaka, S 2024, 'Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study', JCO Global Oncology, vol. 10, e2300392. https://doi.org/10.1200/GO.23.00392

TY - JOUR

T1 - Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy

T2 - A Nationwide Observational Study

AU - Nishikawa, Yoshitaka

AU - Horimatsu, Takahiro

AU - Oka, Shiro

AU - Yamada, Takeshi

AU - Mitsui, Keigo

AU - Yamamoto, Hironori

AU - Takahashi, Keiichi

AU - Shiomi, Akio

AU - Hotta, Kinichi

AU - Takeuchi, Yoji

AU - Kuwai, Toshio

AU - Ishida, Fumio

AU - Kudo, Shin Ei

AU - Saito, Shoichi

AU - Ueno, Masashi

AU - Sunami, Eiji

AU - Yamano, Tomoki

AU - Itabashi, Michio

AU - Ohtsuka, Kazuo

AU - Kinugasa, Yusuke

AU - Matsumoto, Takayuki

AU - Sugai, Tamotsu

AU - Uraoka, Toshio

AU - Kurahara, Koichi

AU - Yamaguchi, Shigeki

AU - Kato, Tomohiro

AU - Okajima, Masazumi

AU - Kashida, Hiroshi

AU - Fujita, Fumihiko

AU - Ikematsu, Hiroaki

AU - Ito, Masaaki

AU - Esaki, Motohiro

AU - Kawai, Masaya

AU - Yao, Takashi

AU - Hamada, Madoka

AU - Koda, Keiji

AU - Fukai, Yasumori

AU - Komori, Koji

AU - Saitoh, Yusuke

AU - Kanemitsu, Yukihide

AU - Takamaru, Hiroyuki

AU - Yamada, Kazutaka

AU - Nozawa, Hiroaki

AU - Takayama, Tetsuji

AU - Togashi, Kazutomo

AU - Shinto, Eiji

AU - Torisu, Takehiro

AU - Toyoshima, Akira

AU - Ohmiya, Naoki

AU - Kato, Takeshi

AU - Otsuji, Eigo

AU - Nagata, Shinji

AU - Hashiguchi, Yojiro

AU - Sugihara, Kenichi

AU - Ajioka, Yoichi

AU - Tanaka, Shinji

PY - 2024

Y1 - 2024

N2 - PURPOSELimited information is available regarding the characteristics and outcomes of stage IV small bowel adenocarcinoma (SBA) in Japan. This study examined the clinical and pathological characteristics and outcomes according to the treatment strategies in patients with stage IV SBA.METHODSThis retrospective observational study used the data of patients with jejunal or ileal adenocarcinoma collected by the Small Bowel Malignant Tumor Project of the Japanese Society for Cancer of the Colon and Rectum. Descriptive statistics were expressed as the mean (standard deviation) or median (range). Survival analysis was performed using Kaplan-Meier curves and pairwise log-rank tests.RESULTSData from 128 patients were analyzed. The treatment strategies were chemotherapy alone (26 of 128, 20.3%), surgery alone (including palliative surgery; 21 of 128, 16.4%), surgery + chemotherapy (74 of 128, 57.8%), and best supportive care (7 of 128, 5.5%). The median (range) overall survival was 16 (0-125) months overall, and 11 (1-38) months, 8 (0-80) months, 18 (0-125) months, and 0 (0-1) months for the chemotherapy, surgery, surgery + chemotherapy, and best supportive care groups, respectively. Three main categories of chemotherapeutic regimen were used: a combination of fluoropyrimidine and oxaliplatin (F + Ox), fluoropyrimidine and irinotecan (F + Iri), and single-agent fluoropyrimidine. Among patients treated with chemotherapy, the median (range) OS was 16 (1-106) months overall, and 17 (1-87) months, 29 (7-39) months, and 16 (1-106) months in patients treated with fluoropyrimidine, F + Iri, and F + Ox, respectively.CONCLUSIONPatients treated with surgery, chemotherapy, or both had a better prognosis than those who received best supportive care. Among patients who received chemotherapy, survival did not differ according to the chemotherapeutic regimen.

AB - PURPOSELimited information is available regarding the characteristics and outcomes of stage IV small bowel adenocarcinoma (SBA) in Japan. This study examined the clinical and pathological characteristics and outcomes according to the treatment strategies in patients with stage IV SBA.METHODSThis retrospective observational study used the data of patients with jejunal or ileal adenocarcinoma collected by the Small Bowel Malignant Tumor Project of the Japanese Society for Cancer of the Colon and Rectum. Descriptive statistics were expressed as the mean (standard deviation) or median (range). Survival analysis was performed using Kaplan-Meier curves and pairwise log-rank tests.RESULTSData from 128 patients were analyzed. The treatment strategies were chemotherapy alone (26 of 128, 20.3%), surgery alone (including palliative surgery; 21 of 128, 16.4%), surgery + chemotherapy (74 of 128, 57.8%), and best supportive care (7 of 128, 5.5%). The median (range) overall survival was 16 (0-125) months overall, and 11 (1-38) months, 8 (0-80) months, 18 (0-125) months, and 0 (0-1) months for the chemotherapy, surgery, surgery + chemotherapy, and best supportive care groups, respectively. Three main categories of chemotherapeutic regimen were used: a combination of fluoropyrimidine and oxaliplatin (F + Ox), fluoropyrimidine and irinotecan (F + Iri), and single-agent fluoropyrimidine. Among patients treated with chemotherapy, the median (range) OS was 16 (1-106) months overall, and 17 (1-87) months, 29 (7-39) months, and 16 (1-106) months in patients treated with fluoropyrimidine, F + Iri, and F + Ox, respectively.CONCLUSIONPatients treated with surgery, chemotherapy, or both had a better prognosis than those who received best supportive care. Among patients who received chemotherapy, survival did not differ according to the chemotherapeutic regimen.

UR - http://www.scopus.com/inward/record.url?scp=85184670907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85184670907&partnerID=8YFLogxK

U2 - 10.1200/GO.23.00392

DO - 10.1200/GO.23.00392

M3 - Article

C2 - 38330276

AN - SCOPUS:85184670907

SN - 2378-9506

VL - 10

JO - JCO Global Oncology

JF - JCO Global Oncology

M1 - e2300392

ER -

Outcomes of Metastatic and Unresectable Small Bowel Adenocarcinoma in Japan According to the Treatment Strategy: A Nationwide Observational Study

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this